Atrium Therapeutics develops RNA therapeutics designed for targeted delivery to heart tissue. The biopharmaceutical company focuses on precision cardiology programs for rare genetic cardiomyopathies, including candidates ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, and uses ligand-based targeting approaches with oligonucleotide-based therapies.
Recurring Atrium news covers RNA delivery-platform development, cardiology research collaborations, clinical and regulatory preparation, capital-structure updates and governance matters such as equity inducement grants. Company updates also include milestone activity under its global cardiovascular collaboration with Bristol Myers Squibb and public-company developments following Atrium's launch as an independent Nasdaq-listed issuer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Avidity Biosciences (Nasdaq: RNA) has received FDA Fast Track designation for its RNA therapeutic, AOC 1044, intended for treating Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping (DMD44). This designation promotes expedited development and review processes due to the serious nature of DMD, which lacks approved therapies targeting exon 44. AOC 1044 is currently in a Phase 1/2 clinical trial, EXPLORE44™, which aims to evaluate its safety and efficacy. The trial will involve around 64 participants, including healthy volunteers and DMD patients, and results are expected in late 2023. Avidity emphasizes its ongoing commitment to deliver effective treatments for rare diseases, as AOC 1044 is one of several AOCs in development for DMD.
Avidity Biosciences, Inc. (NASDAQ: RNA) announced on April 20, 2023, that its Human Capital Management Committee granted stock options and restricted stock units (RSUs) to 12 new non-executive employees. Specifically, 58,300 stock options and 29,150 RSUs were awarded under the 2022 Employment Inducement Incentive Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $15.75, equal to the closing stock price on the grant date. The options will vest over four years, while the RSUs will vest in four equal installments over four years. Avidity focuses on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), with ongoing clinical trials for several conditions, including myotonic dystrophy and Duchenne muscular dystrophy.
Avidity Biosciences, Inc. (Nasdaq: RNA) announced its upcoming presentations at the 75th American Academy of Neurology (AAN) Annual Meeting occurring in Boston from April 22-27, 2023. Key highlights include an oral presentation on April 27, focusing on the AOC 1001 Phase 1/2 MARINA™ trial, which evaluates the safety, biomarker, and functional data for patients with Myotonic Dystrophy Type 1 (DM1). Additionally, a poster presentation on April 23 will cover the AOC 1020 trial design for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). Avidity's commitment is to advance its RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs™), targeting diseases previously considered untreatable. For more information, visit Avidity's website.
Avidity Biosciences (Nasdaq: RNA) announced an investor and analyst event on April 27, 2023, in Boston, showcasing topline safety, biomarker, and functional data from the AOC 1001 Phase 1/2 MARINA trial for myotonic dystrophy type 1 (DM1). The event, starting at 5:30 p.m. ET, will be accessible via webcast. Lead investigator Nicholas E. Johnson will present this data earlier that day at the 75th American Academy of Neurology Annual Meeting. Avidity’s AOC 1001 aims to address DM1, part of a growing pipeline of innovative RNA therapeutics, which also includes treatments for facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy. The company continues to advance its mission to deliver targeted therapies to previously untreatable diseases.